Loading
A phase 1/2 trial of XZP-5955 tablets in non-small-cell lung cancer, run by Xuanzhu Biopharmaceutical Co., Ltd., now recruiting.
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04996121 by Xuanzhu Biopharmaceutical Co., Ltd., with 360 participants planned, started 2021-12-06 and due to reach its primary completion in 2025-09. Interventions recorded: XZP-5955 tablets.
Shares Xuanzhu Biopharmaceutical and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Xuanzhu Biopharmaceutical and the tag pipeline.
Shares NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.